#drugdev
Check out our Behind-The-Paper article talking about the intersection of #aging target research and drug dev to fill a desperate clinical need for patients with no curative therapeutic options:
communities.springernature.com/posts/ai-mee...

#IPF #drugdev #AI #genAI
AI Meets IPF: Taking an AI-Designed Drug from Target Discovery to Phase IIa
Results from the GENESIS-IPF Phase IIa trial, now published in Nature Medicine, signal the emergence of artificial intelligence-based tools as a practical, efficient paradigm for drug discovery.
communities.springernature.com
June 4, 2025 at 1:47 PM
Finding effective antibodies is massively challenging: starting with *billions* of candidates, yet only a few actually bind to disease targets. 🔑 #drugdev

Source: https://phys.org/news/2026-08-ai-biology-antibodies-drug-discovery.html
August 13, 2026 at 4:22 PM
AI is speeding up early drug discovery, sifting through options where 90% of candidates *fail* before reaching patients. Delivery remains a huge hurdle. 💊 #drugdev

Source: https://phys.org/news/2026-07-ai-drug-discovery-qa.html
July 24, 2026 at 1:42 AM
Hi there, just joined. 👋 Feels better here already #MedSky #ScienceSky #drugdev
November 13, 2024 at 5:36 AM
Tonight at DrugDev Nightmares
May 26, 2026 at 5:53 PM
For some context, we have known for >10 yrs that colibactin (the toxin) induces DNA damage/mutations that would likely drive cancer.

Emily Balskus' work, among others, demonstrated this.

But we are unlikely to have a treatment anytime soon. What gives?

#microbiome #drugDev #infectiousDisease
April 25, 2025 at 5:50 PM
I know bladder cancer is a serious, terrible disease.

But at the same time this J&J slide popped up and I thought: "Would you like a bladder pretzel?"

#drugDev #pharma #ImSorry
April 24, 2025 at 7:05 PM
Some of our recent work on models to design molecular glues, PROTACs (and really anything that forms a protein-protein complex) -- presented by Aram Davtyan at Keystone on Proximity-based Therapeutics this week!

#targetedDegradation #PROTAC #molecularGlue #drugDev #drugDesign #biotech #bioSky
Aram Davtyan giving an awesome poster presentation about our work modeling protein-small molecule-protein ternary complexes at @keystonesymposia.bsky.social Proximity-Based Therapeutics! #biotech #drugDev #degraders #molecularGlues #PROTACs

Find the poster here: www.deeporigin.com/academic-pos...
February 18, 2025 at 9:32 PM
For those working in #cellTherapy, Ori Biotech has created tracker of all patients treated with commercially-available cell therapies.

It hovers around 33,000.

#biotech #pharma #drugDev

oribiotech.com/insight/pati...
Patient Access Tracker | Oribiotech Ltd
Updated December 2024 – Ori has calculated the number of patients treated with commercially available cell therapies
oribiotech.com
January 14, 2025 at 4:42 PM
Something I am always baffled by: Center for Biologics Evaluation and Research (CBER) in the FDA does *NOT* regulate antibody or other protein therapies.

That's done by Center for Drug Evaluation and Research (CDER) - even though they're biologics.

pmc.ncbi.nlm.nih.gov/articles/PMC...

#drugDev
November 17, 2024 at 2:39 AM
Ned David (founder at Syrrix, Kythera, Achaogen, Unity Bio) on founding biotechs, being a drug hunter, and lessons he's learned:

1) capital excess is death
2) do the experiment that would destroy the idea first
3) do not go public unless you're absolutely ready

#biotech #startup #bioSky #drugDev
November 15, 2024 at 3:51 AM
I'm learning some pharmacology, and I don't know if the pharmacologists can be trusted with acronyms.

They have created: PK/PD, PBPK, PBAM, PBBM, QSP, QST...all of which are related but different concepts or frameworks.

Plz folks, no more P's and B's at least.

#pharmacology #bioSky #drugDev
November 10, 2024 at 2:45 AM
We talk a lot about the reasons drug candidates fail, but I feel like we don't talk enough about WHY specific candidates fail.

Things like "lack of efficacy" or "tox" aren't really actionable. Was it binding affinity? Binding to a homolog? Metabolized too fast? A mix?

#BioSky #ChemSky #drugDev
October 11, 2024 at 4:50 PM
Aram Davtyan giving an awesome poster presentation about our work modeling protein-small molecule-protein ternary complexes at @keystonesymposia.bsky.social Proximity-Based Therapeutics! #biotech #drugDev #degraders #molecularGlues #PROTACs

Find the poster here: www.deeporigin.com/academic-pos...
February 18, 2025 at 3:03 PM
Moldovan et al (2026) The Crystal Chemistry and Particle Sciences of Drug Product Processing: The Cambridge Structural Database Meets the Manufacturing Classification System | Cryst Growth Des 26:2939–2955 #CSD #PhysChem #DrugDev #OpenAccess #chemsky 🧪
doi.org/10.1021/acs....
The Crystal Chemistry and Particle Sciences of Drug Product Processing: The Cambridge Structural Database Meets the Manufacturing Classification System
An understanding of the materials science of a new active pharmaceutical ingredient is crucial at the interface between chemical synthesis and drug product development. The physical and chemical properties of a new chemical entity, either as the active pharmaceutical ingredient or the drug product, are strongly influenced by the particle attributes and the underlying crystallization process defined during development. Product performance can be assured only when the active ingredient is delivered to the patient in a chemically and physically stable particle. A structural understanding in this key area allows pharmaceutical organizations to support the selection of the right molecule from discovery, design of the right product during development, and optimization of the manufacturing process in production. Accelerated pharmaceutical development, with clear clinical biomarkers, reduced attrition, increased number of projects, and diversity of dosage forms, will heighten the scientific challenge across the pharmaceutical sciences community, in particular at the interface between the active ingredient and the drug product. In this paper, we reimagine the molecule to medicine journey, highlighting progress on the application of Particle Informatics. We demonstrate the crystallographic data thread through development by linking the Manufacturing Classification System back into the Cambridge Structural Database. This demonstrates the potential for Particle Informatics applications to connect across the chemical, analytical, and formulation disciplines, providing a cornerstone for the accelerated development and manufacture of novel advanced pharmaceutical products.
doi.org
April 24, 2026 at 7:14 AM
Opportunity for #GMP Process Technician at Seda Pharmaceutical Development Services (Cheadle, South Manchester UK) ref: REF0125 | closing: 28-Oct-2025 #DrugDev #chemsky 🧪
sedacms.com/vacancy/gmp-...
GMP Process Technician (REF0125) | Seda CMS
We are currently recruiting for the role of GMP Process Technician in our Seda CMS division.
sedacms.com
October 16, 2025 at 6:28 AM
Opportunity for #formulation scientist at Seda Pharmaceutical Development Services (Manchester UK) ref: REF 1024 | closing 31-Jul-2024 #DrugDev 🧪
www.sedapds.com/vacancy/seni...
Senior Scientist, Formulation (REF 1024) | Seda
Seda Pharmaceutical Development Services (Seda) provides integrated Pharmaceutical Development and Clinical Pharmacology Services to the Biotech sector. Through a combination of laboratory, modelling ...
www.sedapds.com
July 4, 2024 at 6:39 AM